GlassScriptPhysician profile
Adrian Salinas
NPI 1730445628
$10,934.76
in general payments reported to CMS, 2019-2025
18 companies · $9,217 in 2025
The $9,217 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $21.29 · 2021: $161 · 2022: $351 · 2023: $454 · 2024: $508 · 2025: $9,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,000 · Food and Beverage: $1,478 · Travel and Lodging: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,000.00 |
| Food and Beverage | $1,478.12 |
| Travel and Lodging | $701.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtual Incision Corporation | $8,941.68 | 2025 | Mira |
| Abbvie INC. | $456.74 | 2019-2025 | Lo Loestrin Fe, Liletta |
| Shield Therapeutics INC | $304.15 | 2023-2024 | Accrufer |
| Exeltis, USA INC. | $182.98 | 2021-2025 | Slynd |
| Coopersurgical, INC. | $175.47 | 2019-2024 | Summit Doppler, Sos, Advincula Delineator Uterine Manipulator |
| Mayne Pharma Commercial LLC | $164.60 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $118.38 | 2023-2025 | Myfembree, Gemtesa |
| Organon LLC | $116.12 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $108.39 | 2021-2022 | |
| Allergan, INC. | $73.84 | 2019 | |
| Evofem Biosciences, INC. | $56.38 | 2021-2025 | Phexxi, Solosec, Phexx |
| Duchesnay USA Incorporated | $40.33 | 2019 | |
| Dexcom, INC. | $37.45 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $36.73 | 2025 | Veozah |
| Teleflex LLC | $36.12 | 2025 | Quikclot |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $32.82 | 2025 | Perclot |
| Smith+Nephew, INC. | $27.77 | 2024 | Stravix |
| Sage Therapeutics, LLC | $24.81 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Salinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.